Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December

Savara Inc. (NASDAQ:SVRA) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 20,185,493 shares, an increase of 33.1% from the November 30th total of 15,166,976 shares. Based on an average daily volume of 4,247,790 shares, the short-interest ratio is currently 4.8 days. Approximately 10.5% of the shares of the company are short sold. Approximately 10.5% of the shares of the company are short sold. Based on an average daily volume of 4,247,790 shares, the short-interest ratio is currently 4.8 days.

Analyst Ratings Changes

A number of research analysts have recently commented on SVRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. HC Wainwright upped their price target on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. UBS Group set a $10.00 price objective on Savara in a research report on Tuesday, December 23rd. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Citigroup reiterated an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Savara Price Performance

SVRA stock traded down $0.17 during midday trading on Tuesday, reaching $6.17. 337,956 shares of the company’s stock traded hands, compared to its average volume of 1,585,842. Savara has a 1-year low of $1.89 and a 1-year high of $7.01. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -11.63 and a beta of 0.22. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The company has a 50-day simple moving average of $5.27 and a two-hundred day simple moving average of $3.76.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Several institutional investors have recently modified their holdings of SVRA. Sivia Capital Partners LLC lifted its holdings in Savara by 9.1% in the second quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock valued at $95,000 after buying an additional 3,459 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Savara by 17.6% during the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after purchasing an additional 5,687 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Savara by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the last quarter. Finally, Sio Capital Management LLC increased its holdings in Savara by 1.0% in the second quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after purchasing an additional 7,197 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.